Best Peptides for Muscle Growth Research: Evidence-Based Analysis
Shop Our Top Compounds
Best Peptides for Muscle Growth Research: Evidence-Based Analysis
Best Peptides for Muscle Growth Research: Evidence-Based Analysis
Introduction
The scientific investigation of peptides for muscle growth research has become one of the most active and promising frontiers in biomedical science. From growth hormone secretagogues that amplify endogenous anabolic signaling to myostatin inhibitors that remove the body’s natural brakes on hypertrophy, researchers have identified a diverse array of peptide compounds with remarkable potential for modulating skeletal muscle mass, strength, and recovery.
Understanding which peptides demonstrate the strongest evidence for muscle-related outcomes is essential for researchers designing preclinical and translational studies. The compounds examined in this analysis span multiple mechanisms of action β including direct growth factor signaling, growth hormone axis stimulation, myostatin pathway inhibition, and tissue repair acceleration β providing a comprehensive overview of the current research landscape.
This article presents an evidence-based analysis of the top 10 peptides studied for muscle growth and hypertrophy, drawing from peer-reviewed publications indexed in PubMed, NIH-funded research, and leading scientific journals. Each peptide is evaluated based on its mechanism of action, key research findings, and muscle-specific data from published studies. All information presented is for research purposes only and is not intended as medical advice or therapeutic guidance.
For a deeper understanding of peptide terminology, visit our Peptide Glossary.
Myostatin Inhibitors and Direct Growth Factor Peptides for Muscle Growth Research
1. Follistatin-344: The Myostatin Antagonist
Mechanism of Action
Follistatin-344 (FS-344) is an alternatively spliced isoform of the follistatin gene that functions as a potent endogenous antagonist of myostatin (GDF-8) and activin A β two members of the TGF-Ξ² superfamily that serve as negative regulators of skeletal muscle growth. By binding and neutralizing these ligands, follistatin effectively removes the molecular brakes on muscle hypertrophy.
The FS-344 transcript encodes a 315-amino acid mature peptide (FS-315) that is secreted from muscle cells and circulates in serum. Unlike the shorter FS-288 isoform, FS-315 does not bind to cell-surface heparan sulfate proteoglycans, thereby avoiding off-target effects on the hypothalamic-pituitary-gonadal axis and reproductive function.
Key Research Findings
Research conducted by Rodino-Klapac, Haidet, and Mendell demonstrated that a single administration of AAV-delivered FS-344 in mice produced sustained increases in hindlimb muscle mass and grip strength for over two years, with treated animals exhibiting significantly greater muscle size across all measured muscle groups compared to controls (Rodino-Klapac et al., 2009).
In a landmark translational study, Kota et al. (2009) reported that follistatin gene delivery in nonhuman primates produced significant increases in muscle size and strength, with quadriceps muscle volume increasing by over 15% in treated animals. Critically, no adverse effects on reproductive function or organ pathology were observed.
Rodino-Klapac LR, Haidet AM, Kota J, et al. βInhibition of myostatin with emphasis on follistatin as a therapy for muscle disease.β Muscle & Nerve, 39(3), 283-296, 2009. DOI: 10.1002/mus.21244
Kota J, Handy CR, Haidet AM, et al. βFollistatin gene delivery enhances muscle growth and strength in nonhuman primates.β Science Translational Medicine, 1(6), 6ra15, 2009. DOI: 10.1126/scitranslmed.3000112
2. IGF-1 LR3: Extended-Action Insulin-Like Growth Factor
Mechanism of Action
IGF-1 LR3 (Long R3 Insulin-Like Growth Factor-1) is a synthetic analog of human IGF-1 with an arginine substitution at position 3 and a 13-amino acid N-terminal extension. These modifications dramatically reduce binding affinity to IGF-binding proteins (IGFBPs), resulting in a significantly extended half-life and greater bioavailability compared to native IGF-1.
IGF-1 activates the PI3K/Akt/mTOR signaling cascade β the central pathway governing skeletal muscle protein synthesis. Additionally, Akt-mediated phosphorylation of FoxO transcription factors suppresses expression of E3 ubiquitin ligases (MAFbx/Atrogin-1 and MuRF1), thereby inhibiting the ubiquitin-proteasome system responsible for muscle protein degradation.
Key Research Findings
A comprehensive review by Yoshida and Delafontaine (2020) confirmed that IGF-1 regulates both anabolic and catabolic pathways in skeletal muscle, with evidence demonstrating increased protein synthesis via PI3K/Akt/mTOR and PI3K/Akt/GSK3Ξ² pathways, while simultaneously inhibiting proteolytic degradation through FoxO suppression.
Research by Velloso (2008) established that IGF-1 plays a critical role in post-exercise muscle repair and hypertrophy, with local IGF-1 expression increasing substantially following mechanical loading in both animal and human muscle tissue.
Yoshida T, Delafontaine P. βMechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy.β Cells, 9(9), 1970, 2020. DOI: 10.3390/cells9091970
Velloso CP. βRegulation of muscle mass by growth hormone and IGF-I.β Frontiers in Physiology, front matter, 2008. DOI: 10.1113/jphysiol.2007.146787
3. MGF (Mechano Growth Factor): The Muscle Repair Splice Variant
Mechanism of Action
Mechano Growth Factor (MGF), also designated IGF-1Ec in humans (IGF-1Eb in rodents), is a splice variant of the IGF-1 gene produced in response to mechanical loading and muscle damage. MGF contains a unique 24-amino acid E-peptide domain resulting from a 49-base pair insert that creates a reading frame shift, generating a distinct C-terminal extension not found in other IGF-1 isoforms.
The MGF E-peptide specifically activates quiescent muscle satellite cells β the resident stem cells responsible for muscle repair and regeneration. This satellite cell activation is a prerequisite for muscle fiber repair and hypertrophic adaptation following exercise or injury.
Key Research Findings
Kandalla et al. (2011) demonstrated that the MGF E-peptide significantly increases the proliferative lifespan and delays senescence of satellite cells isolated from neonatal and young adult human muscle. The peptide enhanced satellite cell activation, proliferation, and fusion, with the effects being most pronounced in younger tissue.
Ates et al. (2007) reported that MGF increases progenitor cells in both normal and dystrophic muscle models, suggesting its role extends beyond simple repair to active muscle regeneration.
Kandalla PK, Goldspink G, Butler-Browne G, Mouly V. βMechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and increases the proliferative life span of satellite cells.β Mechanisms of Ageing and Development, 132(4), 154-162, 2011. DOI: 10.1016/j.mad.2011.02.007
Growth Hormone Secretagogues and Peptides for Muscle Growth Research
4. CJC-1295/Ipamorelin: Synergistic GH Secretagogue Stack
Mechanism of Action
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) modified with a Drug Affinity Complex (DAC) that confers an extended half-life of 5.8β8.1 days β compared to minutes for native GHRH. It binds the GHRH receptor on anterior pituitary somatotrophs to stimulate growth hormone (GH) synthesis and release.
Ipamorelin is a selective growth hormone secretagogue receptor (GHS-R/ghrelin receptor) agonist that triggers acute GH pulses without significantly affecting cortisol or prolactin. When combined, CJC-1295 provides sustained baseline GH elevation while ipamorelin amplifies pulsatile GH release, producing a synergistic effect that more closely mimics physiological GH secretion patterns.
Key Research Findings
In a pivotal randomized, placebo-controlled, double-blind trial, Teichman et al. (2006) demonstrated that subcutaneous administration of CJC-1295 produced dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 or more days, and IGF-1 concentrations increased by 1.5- to 3-fold for 9β11 days following a single injection. After multiple doses, mean IGF-1 levels remained elevated above baseline for up to 28 days.
Teichman SL, Neale A, Lawrence B, et al. βProlonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.β Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805, 2006. DOI: 10.1210/jc.2005-1536
5. MK-677 (Ibutamoren): Oral Growth Hormone Secretagogue
Mechanism of Action
MK-677 (Ibutamoren mesylate) is an orally active, non-peptide ghrelin mimetic that stimulates GH secretion by activating the growth hormone secretagogue receptor (GHS-R1a). Unlike injectable GH secretagogues, MK-677 offers oral bioavailability and sustained activity with once-daily dosing. It enhances pulsatile GH secretion while preserving the natural circadian rhythm of GH release, and also stimulates appetite through ghrelin receptor activation.
Key Research Findings
In a landmark 2-year, double-blind, randomized, placebo-controlled clinical trial, Nass et al. (2008) studied 65 healthy adults aged 60β81. Daily oral administration of MK-677 at 25 mg significantly increased GH and IGF-1 levels to those of healthy young adults. Fat-free mass increased by 1.1 kg in the MK-677 group compared to a 0.5 kg decrease in placebo (P < 0.001). Intracellular water β a marker of body cell mass β also increased significantly.
An earlier study by Svensson et al. (1998) in obese subjects confirmed that two-month administration of MK-677 produced sustained increases in serum GH, IGF-1, and IGF-binding protein-3 levels, while also reversing diet-induced negative nitrogen balance β a key indicator of muscle protein preservation.
Nass R, Pezzoli SS, Oliveri MC, et al. βEffects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.β Annals of Internal Medicine, 149(9), 601-611, 2008. DOI: 10.7326/0003-4819-149-9-200811040-00003
Svensson J, LΓΆnn L, Jansson JO, et al. βTwo-month treatment of obese subjects with the oral growth hormone secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.β Journal of Clinical Endocrinology & Metabolism, 83(2), 362-369, 1998. DOI: 10.1210/jcem.83.2.4539
6. GHRP-6 (Growth Hormone Releasing Peptide-6)
Mechanism of Action
GHRP-6 is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that stimulates growth hormone release through the ghrelin/GHS receptor pathway, independent of the GHRH receptor. It triggers robust GH pulses from the anterior pituitary while simultaneously suppressing somatostatin β the endogenous GH inhibitor. GHRP-6 also exhibits cytoprotective properties and stimulates appetite through ghrelin receptor-mediated mechanisms.
Key Research Findings
Bowers et al. (1991) established that GHRP-6 produces dose-dependent GH release in humans, with the response being synergistic when combined with GHRH. Research has demonstrated that GHRP-6 administration increases circulating GH levels by 5- to 16-fold above baseline, depending on the dosage utilized.
In therapeutic research, Berlanga et al. (2016) demonstrated that GHRP-6 possesses significant tissue repair properties, including enhanced healing processes and reduced fibrotic tissue formation in experimental models, suggesting applications beyond simple GH stimulation.
Bowers CY, Reynolds GA, Durham D, et al. βGrowth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone.β Journal of Clinical Endocrinology & Metabolism, 70(4), 975-982, 1990. DOI: 10.1210/jcem-70-4-975
Berlanga-Acosta J, Abreu-Cruz A, et al. βGrowth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds.β Plastic Surgery International, 2016, 7340426, 2016. DOI: 10.1155/2016/7340426
Tissue Repair and Recovery Peptides for Muscle Growth Research
7. BPC-157: The Tissue Repair Peptide
Mechanism of Action
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a sequence found in human gastric juice. Its mechanism involves upregulation of growth hormone receptor expression, activation of the FAK-paxillin pathway in tendon fibroblasts, promotion of angiogenesis through VEGF and FGF2 upregulation, and modulation of the nitric oxide (NO) system. BPC-157 also interacts with the dopaminergic, serotonergic, and GABAergic systems.
Key Research Findings
Chang et al. (2011) demonstrated that BPC-157 significantly enhances tendon fibroblast outgrowth, migration, and collagen production, with treated tendon explants showing accelerated healing and improved mechanical properties. The research revealed that BPC-157 promotes healing by upregulating growth factor receptor expression on tendon cells.
In a comprehensive review, Gwyer et al. (2019) analyzed the totality of BPC-157 research and concluded that all studies demonstrated βconsistently positive and prompt healing effects for various injury types,β including muscle, tendon, ligament, and bone injuries. Cerovecki et al. (2010) further confirmed that BPC-157 improves medial collateral ligament healing throughout a 90-day observation period following surgical transection in animal models.
For more on BPC-157, see our BPC-157 Complete Guide and explore our BPC-157 research products.
Chang CH, Tsai WC, Lin MS, et al. βThe promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.β Journal of Applied Physiology, 110(3), 774-780, 2011. DOI: 10.1152/japplphysiol.00945.2010
Gwyer D, Wragg NM, Wilson SL. βGastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.β Cell and Tissue Research, 377(2), 153-159, 2019. DOI: 10.1007/s00441-019-03016-8
8. TB-500 (Thymosin Beta-4): Actin Regulation and Regeneration
Mechanism of Action
TB-500 is a synthetic fragment of Thymosin Beta-4 (TΞ²4), a 43-amino acid peptide that is the primary intracellular G-actin sequestering molecule. By regulating the polymerization state of actin, TΞ²4 plays a fundamental role in cell migration, proliferation, and differentiation. TB-500 promotes tissue repair through multiple mechanisms: stimulating angiogenesis, reducing inflammation via downregulation of pro-inflammatory cytokines, suppressing apoptosis, and activating resident stem and progenitor cells.
Key Research Findings
Malinda et al. (1999) demonstrated that Thymosin Beta-4 accelerates wound healing in a rat full-thickness wound model, with treated wounds showing significantly increased rates of re-epithelialization and collagen deposition. The study established TΞ²4 as a potent pro-healing molecule with angiogenic properties.
Smart et al. (2011) reported that Thymosin Beta-4 is the first known molecule capable of initiating simultaneous myocardial and vascular regeneration after systemic administration, with implications for cardiac muscle repair that may extend to skeletal muscle applications.
Malinda KM, Sidhu GS, Mani H, et al. βThymosin beta4 accelerates wound healing.β Journal of Investigative Dermatology, 113(3), 364-368, 1999. DOI: 10.1046/j.1523-1747.1999.00708.x
Smart N, Risebro CA, Melville AA, et al. βThymosin beta4 and cardiac repair.β Annals of the New York Academy of Sciences, 1194, 87-96, 2010. DOI: 10.1111/j.1749-6632.2010.05491.x
Browse our selection of TB-500 research peptides for your laboratory studies.
Specialized GH Secretagogues and Peptides for Muscle Growth Research
9. Hexarelin: Potent GH Release with Cardiac Benefits
Mechanism of Action
Hexarelin (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide growth hormone secretagogue that activates the GHS-R1a receptor to stimulate pituitary GH release. Notably, hexarelin also binds to a distinct cardiac receptor β the scavenger receptor CD36 β which mediates GH-independent cardioprotective effects. This dual-receptor activity makes hexarelin unique among GH secretagogues, as it possesses direct cardiovascular benefits separate from its GH-stimulating properties.
Key Research Findings
Bisi et al. (1999) reported that hexarelin produces acute cardiovascular and hormonal effects in human subjects, including increased cardiac output and left ventricular ejection fraction, independent of its effects on GH secretion.
In a key preclinical study, Broglio et al. (2000) demonstrated that hexarelin improves cardiac function in rats after experimental myocardial infarction, with treated animals showing increased stroke volume, increased cardiac output, and decreased total peripheral resistance compared to saline controls. Locatelli et al. (1999) further established that hexarelin’s cardioprotective effects occur independently of GH by demonstrating similar cardiac protection in hypophysectomized rats lacking a functional GH axis.
Broglio F, Bisi G, et al. βThe growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction.β Endocrinology, 141(1), 60-66, 2000. DOI: 10.1210/endo.141.1.7249
Locatelli V, Rossoni G, Schweiger F, et al. βGrowth hormone-independent cardioprotective effects of hexarelin in the rat.β Endocrinology, 140(9), 4024-4031, 1999. DOI: 10.1210/endo.140.9.6948
10. Tesamorelin: FDA-Approved GHRH Analog
Mechanism of Action
Tesamorelin is a synthetic analog of human GHRH (growth hormone-releasing hormone) consisting of the full 44-amino acid GHRH sequence with an added trans-3-hexenoic acid modification at the N-terminus. This modification increases stability and resistance to enzymatic degradation while preserving full GHRH receptor agonist activity. Tesamorelin stimulates pituitary somatotrophs to produce and release GH, which in turn increases hepatic IGF-1 production, creating downstream anabolic effects on muscle and bone while reducing visceral adipose tissue.
Key Research Findings
Stanley et al. (2019) conducted an exploratory analysis demonstrating that tesamorelin significantly increases muscle quality (density) and quantity (cross-sectional area) in HIV-associated lipodystrophy. Thigh muscle density improved significantly in tesamorelin-treated subjects compared to placebo, indicating improved muscle quality beyond simple mass changes.
In a Phase III clinical trial, Falutz et al. (2007) established that tesamorelin significantly reduces visceral adipose tissue while improving body composition markers and increasing IGF-1 levels. Notably, tesamorelin is the only GHRH analog with FDA approval for clinical use, providing a unique benchmark for the GH secretagogue class.
Stanley TL, Feldpausch MN, Oh J, et al. βThe Growth Hormone Releasing Hormone Analogue, Tesamorelin, Improves Muscle Quality and Quantity in HIV-Associated Lipodystrophy.β AIDS, 33(12), 1831-1839, 2019. DOI: 10.1097/QAD.0000000000002287
Falutz J, Allas S, Blot K, et al. βTesamorelin, a human growth hormone releasing factor analogue, reduces abdominal fat in HIV-infected patients with lipodystrophy.β Future HIV Therapy, 2(1), 29-39, 2008. DOI: 10.2217/17469600.2.1.29
Comparative Analysis: Peptides for Muscle Growth Research at a Glance
Peptide | Primary Mechanism | Route | Key Muscle Outcome | Evidence Level |
|---|---|---|---|---|
Follistatin-344 | Myostatin/activin inhibition | Gene delivery / SC | Increased muscle mass 15β30% in primates | Preclinical (strong) |
IGF-1 LR3 | PI3K/Akt/mTOR activation | SC/local injection | Enhanced protein synthesis, reduced catabolism | Preclinical + review |
MGF | Satellite cell activation | SC/local injection | Increased satellite cell proliferation | Preclinical |
CJC-1295/Ipamorelin | Sustained GH + pulsatile GH release | SC | GH β 2-10x, IGF-1 β 1.5-3x for 9-11 days | Human clinical trial |
MK-677 | Oral ghrelin mimetic | Oral | FFM β 1.1 kg over 12 months in elderly | RCT (2-year) |
GHRP-6 | GHS-R agonist, GH release | SC | GH β 5-16x baseline, appetite stimulation | Human studies |
BPC-157 | Growth factor receptor upregulation | SC/oral | Accelerated tendon/muscle healing | Preclinical (extensive) |
TB-500 | Actin regulation, angiogenesis | SC | Enhanced tissue regeneration, anti-inflammatory | Preclinical |
Hexarelin | GHS-R + CD36 cardiac receptor | SC | GH release + GH-independent cardioprotection | Human + preclinical |
Tesamorelin | GHRH receptor agonist | SC | Improved muscle quality + reduced visceral fat | RCT (FDA-approved) |
Frequently Asked Questions: Peptides for Muscle Growth Research
What are the most-studied peptides for muscle growth research?
The most extensively studied peptides for muscle growth research include IGF-1 and its analogs (IGF-1 LR3, MGF), growth hormone secretagogues (CJC-1295, Ipamorelin, MK-677, GHRP-6, hexarelin), myostatin inhibitors (follistatin-344), tissue repair peptides (BPC-157, TB-500), and the FDA-approved GHRH analog tesamorelin. Each operates through distinct mechanisms and has varying levels of preclinical and clinical evidence supporting its effects on skeletal muscle tissue.
How does follistatin-344 promote muscle growth in research models?
In published research studies, follistatin-344 promotes muscle growth by binding and neutralizing myostatin and activin A β both negative regulators of muscle mass in the TGF-Ξ² superfamily. Research by Kota et al. (2009) demonstrated that follistatin gene delivery in nonhuman primates produced significant increases in muscle volume exceeding 15%, with improvements in grip strength and no adverse effects on reproductive function. This peptide is available for research purposes only.
What evidence supports MK-677 for lean body mass research?
A 2-year randomized, placebo-controlled clinical trial by Nass et al. (2008) in 65 healthy adults aged 60β81 demonstrated that daily oral MK-677 at 25 mg increased fat-free mass by 1.1 kg (vs. -0.5 kg placebo, P < 0.001) while elevating GH and IGF-1 to young-adult levels. These findings are from controlled research settings. MK-677 is classified as a research compound and is not approved for therapeutic use.
Can BPC-157 support muscle repair in research settings?
Published preclinical studies consistently demonstrate that BPC-157 accelerates healing of muscle, tendon, and ligament injuries in animal models. Research by Gwyer et al. (2019) reviewing the BPC-157 literature concluded that all published studies showed βconsistently positive and prompt healing effects.β The peptide is believed to work through upregulation of growth factor receptors and promotion of angiogenesis. BPC-157 is sold for research purposes only and is not for human consumption.
What is the difference between CJC-1295 and Ipamorelin?
CJC-1295 is a GHRH analog with an extended half-life of 5.8β8.1 days that provides sustained GH elevation, while Ipamorelin is a selective ghrelin receptor agonist that produces acute GH pulses. In research protocols, they are frequently combined because CJC-1295 maintains elevated baseline GH while Ipamorelin amplifies pulsatile release, mimicking physiological GH secretion more closely than either compound alone.
How does hexarelin differ from other growth hormone secretagogues?
Hexarelin is unique among GH secretagogues because it binds to both the GHS-R1a receptor (stimulating GH release) and the cardiac CD36 receptor (providing direct cardioprotection). Research by Locatelli et al. (1999) demonstrated that hexarelin preserves cardiac function even in hypophysectomized animals lacking GH production, confirming that its cardioprotective effects are GH-independent.
What role does IGF-1 play in muscle hypertrophy research?
IGF-1 is a central regulator of skeletal muscle mass, activating the PI3K/Akt/mTOR pathway to stimulate protein synthesis while simultaneously inhibiting protein degradation through suppression of FoxO-mediated ubiquitin ligase expression. As reviewed by Yoshida and Delafontaine (2020), IGF-1 also promotes muscle regeneration via satellite cell activation, making it a multi-faceted target for hypertrophy and atrophy research.
Are there FDA-approved peptides for body composition research?
Tesamorelin is the only GHRH analog with FDA approval (for treatment of HIV-associated lipodystrophy). Clinical trials demonstrated that tesamorelin reduces visceral adipose tissue while improving lean body mass and muscle quality. It serves as an important reference compound for researchers studying the GH-IGF-1 axis and body composition modification.
Conclusion: The Future of Peptides for Muscle Growth Research
The landscape of peptides for muscle growth research continues to expand as new mechanisms are elucidated and existing compounds are better characterized through rigorous preclinical and clinical investigation. From the dramatic muscle-building effects of follistatin-344’s myostatin inhibition to the clinically validated lean mass improvements with MK-677, and from the tissue repair capabilities of BPC-157 and TB-500 to the sophisticated GH axis modulation achieved by CJC-1295/Ipamorelin combinations, researchers have an unprecedented toolkit for studying skeletal muscle biology.
The evidence presented in this analysis underscores several important themes: (1) multiple complementary mechanisms can be leveraged to influence muscle growth pathways, (2) the GH-IGF-1 axis remains a central target with diverse entry points for modulation, (3) tissue repair peptides like BPC-157 and TB-500 address the critical recovery component of muscle adaptation, and (4) compounds like tesamorelin with FDA approval provide clinical validation that GHRH-based approaches can meaningfully alter body composition.
As research methodologies advance and more human clinical data becomes available, the translational potential of these peptides for muscle growth research will continue to be refined. Researchers interested in incorporating these compounds into their laboratory investigations can explore Iron Peak Peptides’ complete catalog of research-grade peptides including BPC-157, TB-500, and other compounds discussed in this analysis.
All compounds referenced in this article are intended for research purposes only and are not for human consumption.
Research References
Rodino-Klapac LR, Haidet AM, Kota J, et al. βInhibition of myostatin with emphasis on follistatin as a therapy for muscle disease.β Muscle & Nerve, 39(3), 283-296, 2009. DOI: 10.1002/mus.21244
Kota J, Handy CR, Haidet AM, et al. βFollistatin gene delivery enhances muscle growth and strength in nonhuman primates.β Science Translational Medicine, 1(6), 6ra15, 2009. DOI: 10.1126/scitranslmed.3000112
Yoshida T, Delafontaine P. βMechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy.β Cells, 9(9), 1970, 2020. DOI: 10.3390/cells9091970
Velloso CP. βRegulation of muscle mass by growth hormone and IGF-I.β Frontiers in Physiology, 2008. DOI: 10.1113/jphysiol.2007.146787
Kandalla PK, Goldspink G, Butler-Browne G, Mouly V. βMechano Growth Factor E peptide (MGF-E) activates human muscle progenitor cells.β Mechanisms of Ageing and Development, 132(4), 154-162, 2011. DOI: 10.1016/j.mad.2011.02.007
Teichman SL, Neale A, Lawrence B, et al. βProlonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295.β Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805, 2006. DOI: 10.1210/jc.2005-1536
Nass R, Pezzoli SS, Oliveri MC, et al. βEffects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults.β Annals of Internal Medicine, 149(9), 601-611, 2008. DOI: 10.7326/0003-4819-149-9-200811040-00003
Svensson J, LΓΆnn L, Jansson JO, et al. βTwo-month treatment of obese subjects with the oral growth hormone secretagogue MK-677.β Journal of Clinical Endocrinology & Metabolism, 83(2), 362-369, 1998. DOI: 10.1210/jcem.83.2.4539
Bowers CY, Reynolds GA, Durham D, et al. βGrowth hormone (GH)-releasing peptide stimulates GH release in normal men.β Journal of Clinical Endocrinology & Metabolism, 70(4), 975-982, 1990. DOI: 10.1210/jcem-70-4-975
Berlanga-Acosta J, et al. βGrowth Hormone-Releasing Peptide 6 Enhances the Healing Process.β Plastic Surgery International, 2016, 7340426. DOI: 10.1155/2016/7340426
Chang CH, Tsai WC, Lin MS, et al. βThe promoting effect of pentadecapeptide BPC 157 on tendon healing.β Journal of Applied Physiology, 110(3), 774-780, 2011. DOI: 10.1152/japplphysiol.00945.2010
Gwyer D, Wragg NM, Wilson SL. βGastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.β Cell and Tissue Research, 377(2), 153-159, 2019. DOI: 10.1007/s00441-019-03016-8
Malinda KM, Sidhu GS, Mani H, et al. βThymosin beta4 accelerates wound healing.β Journal of Investigative Dermatology, 113(3), 364-368, 1999. DOI: 10.1046/j.1523-1747.1999.00708.x
Broglio F, Bisi G, et al. βThe growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction.β Endocrinology, 141(1), 60-66, 2000. DOI: 10.1210/endo.141.1.7249
Locatelli V, Rossoni G, Schweiger F, et al. βGrowth hormone-independent cardioprotective effects of hexarelin in the rat.β Endocrinology, 140(9), 4024-4031, 1999. DOI: 10.1210/endo.140.9.6948
Stanley TL, Feldpausch MN, Oh J, et al. βTesamorelin Improves Muscle Quality and Quantity in HIV-Associated Lipodystrophy.β AIDS, 33(12), 1831-1839, 2019. DOI: 10.1097/QAD.0000000000002287
Research Disclaimer
The information presented in this article is intended for educational and research purposes only. The peptides discussed are sold as research chemicals and are not intended for human consumption. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendations.
All research findings described are derived from published peer-reviewed studies conducted in controlled laboratory and clinical settings. Individual results in research settings may vary. Researchers should consult applicable institutional guidelines and regulatory frameworks before designing experiments with these compounds.
Iron Peak Peptides provides research-grade peptides for qualified researchers and institutions. For questions about our products or research applications, contact us at info@ironpeakpeptides.com.
This content has been compiled from peer-reviewed scientific literature and is presented for informational purposes to support the research community. Iron Peak Peptides does not make therapeutic claims about any products sold.
🔬 Explore Research Peptides
- IGF-1 LR3 1mg — $85.00
- Hexarelin 5mg — $49.00
- BAM15 50mg β 60 Tablets — $179.00
- Thymalin 10mg — $65.00
